Emyria Ltd (ASX:EMD) has received Authorised Prescriber approval from the Therapeutic Goods Administration (TGA) for MDMA-assisted therapy in treating post-traumatic stress disorder (PTSD) This means Emyria’s specialist psychiatrist can prescribe MDMA under a strict regulatory framework for PTSD care.
This is a significant milestone, as MDMA-assisted therapy is being explored as a treatment for PTSD, with multiple Phase 3 clinical trials conducted in the USA. The approval allows Emyria to expand its service offerings beyond clinical trials and into real-world treatment
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.28M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 156400 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 17142 | 1 |
View Market Depth
| Last trade - 16.12pm 16/06/2025 (20 minute delay) ? |
| EMD (ASX) Chart |
Day chart unavailable